Orbit Genomics is a cancer diagnostic company developing its proprietary Orbiseq™ platform for early detection, treatment and prevention of complext diseases. The platform analyzes repetitive DNA, which uniquely reflects both inherited and acquired disease risk. The first target is early detection of lung cancer, which is the leading cause of cancer death for both men and women in the US.